WhaleCreep
Home › Funds › Caligan Partners LP › Q2 2025

Caligan Partners LP 13F holdings, Q2 2025

Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →

Caligan Partners LP disclosed 16 US equity positions worth $515.1m in its Q2 2025 13F filing. The largest position was VRNA at 26.4% of the reported book, followed by LQDA and EXEL. Against the Q1 2025 filing, it opened 1 new position, added to 8 and reduced 2 among the top 16 holdings.

← Q1 2025 · Q3 2025 →

What did Caligan Partners LP own in Q2 2025? Top 16 positions

#StockSectorWeightValueSharesΔ sharesvs Q1 2025
1 VRNA VERONA PHARMA PLC 26.4%$135.9m1,436,878 0% held
2 LQDA LIQUIDIA CORPORATION Healthcare 19.6%$101.2m8,118,892 0% held
3 EXEL EXELIXIS INC Healthcare 13.1%$67.2m1,525,730 0% held
4 AGIO AGIOS PHARMACEUTICALS INC Healthcare 6.9%$35.6m1,071,258 53% added
5 MERUS N V 6.7%$34.6m656,999 74% added
6 EOLS EVOLUS INC Healthcare 6.0%$30.8m3,341,970 22% added
7 MLYS MINERALYS THERAPEUTICS INC Healthcare 5.3%$27.3m2,017,352 -6% reduced
8 RVMD REVOLUTION MEDICINES INC Healthcare 4.5%$23.4m636,835 37% added
9 ANIK ANIKA THERAPEUTICS INC Healthcare 2.9%$15.2m1,435,130 0% held
10 ABVX ABIVAX SA 2.5%$12.8m1,674,400 32% added
11 YMABUSD Y-MABS THERAPEUTICS INC 2.1%$10.6m2,342,609 0% held
12 RZLT REZOLUTE INC 1.3%$6.9m1,543,014 992% added
13 BCRX BIOCRYST PHARMACEUTICALS INC Healthcare 1.1%$5.7m638,908 -79% reduced
14 VRCA VERRICA PHARMACEUTICALS INC 1.0%$4.9m9,239,119 3% added
15 TYRA TYRA BIOSCIENCES INC Healthcare 0.4%$1.8m189,950 660% added
16 AURA AURA BIOSCIENCES INC 0.2%$1.3m200,000 – new

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.